Myriad Genetics, Inc. (MYGN)
MYGN moved a median of -0.09% 30 minutes after news, and -0.14% by the close. How MYGN actually reacts to news — the realized, point-in-time move the market made, measured across 560 labeled events over the last three years with zero look-ahead.
MYGN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.10% | 52% | 559 |
| 30-min | -0.09% | 46% | 559 |
| 60-min | -0.28% | 44% | 559 |
| to close | -0.14% | 47% | 549 |
| Middle 50% of MYGN reactions | -1.03% to +0.88% |
|---|---|
| Median reaction (30-min) | -0.09% |
| Measured reactions | 560 |
Half of all Myriad Genetics, Inc. news events land between -1.03% and +0.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MYGN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | +0.92% | 71% | -0.99% |
| Analyst downgrades | 29 | +0.23% | 59% | +0.88% |
| Coverage initiations | 31 | -0.20% | 42% | +1.87% |
| Rating reiterations | 46 | -0.27% | 46% | -0.69% |
| Price-target cuts | 18 | -0.65% | 28% | -0.25% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how MYGN ranks against every other measured name →
That’s how MYGN usually reacts — get an email when it moves on news →Email me when MYGN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MYGN's baseline. Nothing else.
Recent MYGN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K MYRIAD GENETICS INC For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | +0.12% | -2.33% | |
| Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology | Press release | GlobeNewswire | -1.89% | -0.94% | |
| Form 8-K MYRIAD GENETICS INC For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +3.39% | +0.78% | |
| Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | Press release | GlobeNewswire | +3.39% | +0.78% | |
| Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference | Press release | GlobeNewswire | +0.64% | +2.25% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.15% | -0.46% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.17% | +5.28% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | -0.03% | +0.65% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.50% | +0.83% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.50% | +1.33% | |
| Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -0.16% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | +0.47% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.15% | — | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +1.88% | — | |
| MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law | Press release | Business Wire | +1.88% | — | |
| Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.47% | +2.03% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.65% | +3.58% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.16% | +0.80% | |
| Form 10-Q MYRIAD GENETICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +8.00% | -4.67% | |
| Form 8-K MYRIAD GENETICS INC For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | +8.00% | -4.67% | |
| Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Press release | GlobeNewswire | +8.00% | -4.67% | |
| Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026 | Press release | GlobeNewswire | +3.39% | +1.79% | |
| Myriad Genetics Launches FirstGene® Multiple Prenatal Screen | Press release | GlobeNewswire | +0.17% | +1.20% | |
| New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer | Press release | GlobeNewswire | -0.50% | -0.99% | |
| Form 8-K MYRIAD GENETICS INC For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +4.99% | |
| Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication | Press release | GlobeNewswire | +0.91% | +4.99% | |
| Form 8-K MYRIAD GENETICS INC For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | -2.56% | |
| Form S-8 MYRIAD GENETICS INC | SEC filing · Form S-8 | SEC EDGAR | -1.49% | -2.56% | |
| Myriad Genetics Names Raj Jampa as New Chief Technology Officer | Press release | GlobeNewswire | -2.13% | +2.13% | |
| Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.26% | +2.08% | |
| Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI) | Press release | GlobeNewswire | +0.26% | +2.08% | |
| Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life | Press release | GlobeNewswire | +0.00% | -0.83% | |
| Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences | Press release | GlobeNewswire | -2.06% | +3.87% | |
| Form 10-Q MYRIAD GENETICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.01% | -2.84% | |
| Form 8-K MYRIAD GENETICS INC For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +2.01% | -2.84% | |
| Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business | Press release | GlobeNewswire | +2.01% | -2.84% | |
| Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan | Press release | GlobeNewswire | +1.71% | +1.50% | |
| Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026 | Press release | GlobeNewswire | +1.47% | -1.68% | |
| Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 | Press release | GlobeNewswire | +0.00% | -3.01% | |
| Form ARS MYRIAD GENETICS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.47% | +7.01% | |
| Form DEF 14A MYRIAD GENETICS INC For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | +2.47% | +7.01% | |
| Form DEFA14A MYRIAD GENETICS INC | SEC filing · Form DEFA14A | SEC EDGAR | +2.47% | +7.01% | |
| Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan | Press release | GlobeNewswire | +2.17% | +6.74% | |
| Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting | Press release | GlobeNewswire | -1.14% | -6.33% | |
| Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer | Press release | GlobeNewswire | +0.00% | -0.85% | |
| Form EFFECT MYRIAD GENETICS INC | SEC filing · Form EFFECT | SEC EDGAR | +0.78% | +0.39% | |
| Myriad Commercially Launches Precise MRD with Select Community Oncologists | Press release | GlobeNewswire | -1.03% | +8.62% | |
| Form 10-K MYRIAD GENETICS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.45% | +7.90% | |
| Form S-3 MYRIAD GENETICS INC | SEC filing · Form S-3 | SEC EDGAR | +0.45% | +7.90% | |
| Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests | Press release | GlobeNewswire | -12.93% | -20.47% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MYGN section they belong to.
Where else MYGN is measured.
MYGN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| VICAL (VICL) | 574 | -0.00% | 38% |
| Becton, Dickinson and Company (BDX) | 573 | -0.01% | 50% |
| Tilray Brands, Inc. (TLRY) | 558 | -0.32% | 41% |
| PERNIX THERAPEUTICS HOLDINGS (PTX) | 557 | -0.19% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Myriad Genetics, Inc.'s median reaction calculated?
Every labeled MYGN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 560 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of MYGN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MYGN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.